Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Active not recruiting 4Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Burkitt Lymphoma 11Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Waldenstrom Macroglobulinemia 2Smoldering Multiple Myeloma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Down Syndrome 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × Calcium Dobesilate × 90 days × Clear all
NCT05519085 2026-05-27

SUCCESSOR-1

Celgene

Phase 3 Recruiting
810 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05552976 2026-04-01

SUCCESSOR-2

Bristol-Myers Squibb

Phase 3 Active not recruiting
606 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Celgene

Phase 1/2 Active not recruiting
466 enrolled 57 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡